ESMO 2025 | Incidence and management of T-DXd-induced ILD in breast cancer
Jean-Yves Pierga, MD, Institut Curie, Paris, France, discusses the timing of interstitial lung disease (ILD) associated with trastuzumab deruxtecan (T-DXd) in patients with HER2-positive breast cancer. The peak and cumulative incidence occurred at 123 days, or approximately six months in the Phase IV REALITY-01 study (NCT05149014). It is, therefore, important to monitor this side effect in patients, particularly within the first six months to one year of treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The peak and the cumulative incidence of this drug was at 123 days, so six months. So that was the cumulative incidence of this side effect. So that clearly shows that it’s mandatory and really important to monitor this side effect in the patient. But it seems to occur quite rarely after six months or at least one year for this monitoring. So that’s also important in routine practice...
The peak and the cumulative incidence of this drug was at 123 days, so six months. So that was the cumulative incidence of this side effect. So that clearly shows that it’s mandatory and really important to monitor this side effect in the patient. But it seems to occur quite rarely after six months or at least one year for this monitoring. So that’s also important in routine practice.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
